159
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study

, ORCID Icon, , , , , , , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 313-324 | Received 25 Aug 2023, Accepted 08 Mar 2024, Published online: 05 Apr 2024

References

  • Novelli F, Bacci E, Latorre M, et al. Comorbidities are associated with different features of severe asthma. Clin Mol Allergy. 2018;16:25. doi:10.1186/s12948-018-0103-x
  • Seccia V, D’Amato M, Scioscia G, et al. Management of patients with severe asthma and chronic rhinosinusitis with nasal polyps: a multidisciplinary shared approach. J Pers Med. 2022;12(27):1096. doi:10.3390/jpm12071096
  • Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77(1):150–161. doi:10.1111/all.14902
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
  • FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi:10.1016/S2213-2600(17)30344-2
  • Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.e1342. doi:10.1016/j.jaci.2010.04.004
  • Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29. doi:10.1016/j.rmed.2016.01.003
  • Moran AM, Ramakrishnan S, Borg CA, et al. Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma. Am J Respir Crit Care Med. 2020;202(9):1314–1316. doi:10.1164/rccm.202003-0729LE
  • Global Initiative for Asthma. Global strategy for asthma management and prevention; 2022. Available from: https://ginasthma.org/. Accessed July 27, 2023.
  • Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309–1317.e1312. doi:10.1016/j.jaci.2021.08.030
  • Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9(3):260–274. doi:10.1016/S2213-2600(20)30414-8
  • Han JK, Bachert C, Lee SE, et al. Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2022;132(2):265–271. doi:10.1002/lary.29888
  • Chuang CC, Guillemin I, Bachert C, et al. Dupilumab in CRSwNP: responder analysis using clinically meaningful efficacy outcome thresholds. Laryngoscope. 2022;132(2):259–264. doi:10.1002/lary.29911
  • Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item SinoNasal Outcome Test. Clin Otolaryngol. 2009;34(5):447–454. doi:10.1111/j.1749-4486.2009.01995.x
  • Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008
  • Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124(4):719–723.e711. doi:10.1016/j.jaci.2009.06.053
  • Bachert C, Han JK, Wagenmann M, et al. EUFOREA Expert Board Meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36. doi:10.1016/j.jaci.2020.11.013
  • FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
  • Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
  • Lombardo N, Pelaia C, Ciriolo M, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851. doi:10.1177/2058738420950851
  • Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9(12):4371–4380.e4374. doi:10.1016/j.jaip.2021.08.004
  • Tiotiu A, Mendez-Brea P, Ioan I, et al. Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps. Clin Rev Allergy Immunol. 2023;64(2):179–192. doi:10.1007/s12016-022-08938-w
  • Chitguppi C, Patel P, Gandler A, et al. Effect of benralizumab in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a case series. Am J Rhinol Allergy. 2021;35(5):559–567. doi:10.1177/1945892420978351
  • Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171:106080. doi:10.1016/j.rmed.2020.106080